COMMUNIQUÉS West-GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/11/2024
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on October 31, 2024, [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/11/2024
MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
01/11/2024
WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
01/11/2024
Ji’an, Jiangxi, China, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a [...]
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
01/11/2024
IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental health condition [...]
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
01/11/2024
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. The exclusive [...]
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
01/11/2024
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
01/11/2024
Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1, 2024 – Zealand Pharma A/S (Nasdaq [...]
Legend Senior Living® Will Operate Newly Renamed Ridgecrest at Cranberry Woods Senior Living Residence
01/11/2024
WICHITA, Kan., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Legend Senior Living, with headquarters in Wichita, KS, has announced that it has assumed operations of Atria at Cranberry Woods and has renamed the residence Ridgecrest [...]
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
01/11/2024
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31 [...]
Safety Shot Expands Distribution to Chicagoland Grocery Stores
01/11/2024
The Company's rapid alcohol-reducing beverage, Sure Shot, launches in Pete's Fresh Market, Caputo's, Tony's Fresh Market, Festival Foods, and Sunset Foods. JUPITER, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Safety Shot, [...]
Milestone Scientific Expands Commercial Rollout of the CompuFlo® Epidural System with Esteemed Pain Management Physician Dr. Elbaz at Hudson Specialty Care
01/11/2024
Recent Medicare Price Assignment Driving Increased Access to CompuFlo Milestone Scientific to Attend New York and New Jersey Pain Medicine Congress 2024 ROSELAND, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Milestone [...]
Merit Medical Completes Acquisition of Lead Management Portfolio from Cook Medical
01/11/2024
SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical’s lead [...]
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
01/11/2024
CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common [...]
RTI Surgical Completes Acquisition of Collagen Solutions
01/11/2024
RTI Surgical Completes Acquisition of Collagen Solutions ALACHUA, Fla., November 1, 2024 – RTI Surgical ("RTI" or "the Company"), a leading CDMO pushing the boundaries of innovation and tissue engineering to meet [...]
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
01/11/2024
FemBloc issued patent provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth control ATLANTA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical [...]
Galecto Reports Third Quarter 2024 Financial Results
01/11/2024
- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge [...]
Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial
01/11/2024
DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on [...]
Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
01/11/2024
Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic [...]

Pages